Financial Snapshot
This section of the Fusion Pharmaceuticals InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Fusion Pharmaceuticals assumes no responsibility for the accuracy of this data and provides it for informational purposes only.
Beta | (0.72) |
---|---|
Shares Outstanding | 84.7M |
Average Volume (10 days) | 1.5M |
Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
Current Mean Recommendation | Hold |
---|
Strong Buy | 0 | |
---|---|---|
Buy | 0 | |
Hold | 12 | |
Underperform | 0 | |
Sell | 0 |
Recent Insider Transactions
Burak Eric Chief Technology Officer | 63,700 Acquire Jan 4, 2024 |
---|---|
Burak Eric Chief Technology Officer | 106,100 Acquire Jan 4, 2024 |
Valliant John Chief Executive Officer | 192,200 Acquire Jan 4, 2024 |
Valliant John Chief Executive Officer | 320,400 Acquire Jan 4, 2024 |
Rawat Mohit President and CBO | 81,300 Acquire Jan 4, 2024 |